Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Popular heart failure drug may be dangerous for women

Yale University : 30 October, 2002  (New Product)
Digoxin, a drug commonly used to treat patients in heart failure, may pose an increased risk of death for women, according to researchers at Yale School of Medicine.
Published in the October 31 issue of the New England Journal of Medicine, the study showed that digoxin had a different effect on men than women. Although digoxin had no effect on the risk of death in men, women who were taking the drug had a higher risk than women who were taking a placebo (33.1 percent versus 28.9 percent). After accounting for other characteristics that differed between women who were taking digoxin and those who were not, digoxin significantly increased women's relative risk of death by 23 percent.

'These data suggest that digoxin acts differently in men than women,' said Harlan Krumholz, professor of medicine at Yale School of Medicine, director of the Yale-New Haven Hospital Center for Outcomes Research and Evaluation, and the senior author on the study.

'Although digoxin appeared to have no clinically meaningful effect on mortality among men, we found that there was a suggestion of increased harm associated with digoxin use in women,' said the study's first author, Saif Rathore, lecturer in the Department of Internal Medicine. 'This pattern persisted after we accounted for factors that differed between men and women taking digoxin and those who had been taking placebo.'

The study team used data from the Digitalis Investigation Group Trial, a National Heart, Lung, and Blood Institute-sponsored trial of digoxin that was conducted between 1991 and 1996. The DIG trial's main results had shown that digoxin was similar to placebo in terms of reducing mortality, but did decrease patients' risk of hospitalization over an average of 37 months of follow-up.

Digoxin, also marketed as Lanoxin, is one of the most commonly prescribed medications in the United States. 'More than 25 million prescriptions for digoxin are filled in the United States each year. Although some of these are for patients who have atrial fibrillation, a heart rhythm disorder, we think a large proportion of these are for patients with heart failure, and presumably half are being filled by women,' Rathore said.

Krumholz said the findings have important implications for clinical practice. 'Additional evidence is needed to confirm our findings because the DIG trial was not designed to specifically test whether digoxin acted similarly in men and women,' he said. 'However, given that digoxin's only benefit in heart failure patients without atrial fibrillation is a small reduction in hospitalizations, I think the chance that the drug may increase a woman's risk of dying is enough to reconsider its role in treating heart failure for women, particularly given the other drugs, such as beta-blockers, which are available to treat heart failure today.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo